Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.
about
Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring.Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assaysGenetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy.Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa.Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infectionEvolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failureUsing observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapyEvaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in IndiaLong-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modificationAntiretroviral regimens for treatment-experienced patients with HIV-1 infection.Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trialAvoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.Defining treatment failure in resource-rich settings.Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.Dried blood spot testing: filling the gap between antiretroviral treatment & monitoring in India.Triple active antiretroviral regimen including enfuvirtide via the Biojector is effective and safe.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q30944694-3EAFC173-6623-4D58-BB37-BFC0B124FF9DQ33636669-612F6D38-EA3E-4BD8-AEF8-ECF55FB40F92Q33636945-8786344C-0427-47FD-AF8C-06794D8922AFQ34485122-BAB01DDC-15D5-49C0-9BDC-973DCC895668Q35049762-3A609214-DEC5-47A0-B047-419E98738465Q35146353-27478EBC-FC9E-4813-8874-0119507379D4Q35698801-542EA5ED-72E7-49C5-956F-6610A1C5961DQ35882896-30D140A1-1D65-4BC5-BDB9-7379EF336ACBQ36693481-D1D81C7D-C43E-440D-809A-D1AAB08FE37BQ36902291-33F3B18F-BBB5-4A80-89AD-AD8636F7B50AQ37003795-3C595A59-887D-4384-8D1E-3B123FAEB784Q37111827-863DDBFB-CB72-44E1-97FD-7F6161C3D6CFQ37197054-2465F579-247B-46D0-9B91-A94F15711A4FQ37313166-308B9A49-3F41-444C-8CE9-F5640A55B026Q37371248-F54DB6BF-E018-43EB-985F-EF32DE8EE391Q37463958-0B45502D-E46A-40A8-803E-53AB7EBC7A3AQ37667776-05756A10-E1FB-44C3-8A5E-6160FDB5E41EQ39043026-908D688F-5F8A-4973-9410-4A6147A01D88Q39442959-C19CB538-38B0-4C28-87F1-3E37F3E21109Q42995760-80A4A6C6-254C-4F2C-9449-B3E6B78CAEB2Q57180790-0EE924B8-E9A3-432C-87A4-573BFC0A23BF
P2860
Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Rate of viral evolution and ri ...... suppressive treatment regimen.
@en
type
label
Rate of viral evolution and ri ...... suppressive treatment regimen.
@en
prefLabel
Rate of viral evolution and ri ...... suppressive treatment regimen.
@en
P2093
P356
P1476
Rate of viral evolution and ri ...... suppressive treatment regimen.
@en
P2093
Eoin Coakley
Hiroyu Hatano
Jeffrey N Martin
Jodi Weidler
Peter Hunt
Rebecca Hoh
Teri Liegler
P304
P356
10.1086/508655
P407
P577
2006-10-06T00:00:00Z